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Abstract
Background: The study aimed to calculate chest-wall skin dose associated with different frequencies of
bolus applications in post-mastectomy three-dimensional conformal radiotherapy (3D-CRT) and to
provide detailed information in the selection of an appropriate bolus regimen in this clinical setting.
Methods: CT-Simulation scans of 22 post-mastectomy patients were used. Chest wall for clinical target
volume (CTV) and a volume including 2-mm surface thickness of the chest wall for skin structures were
delineated. Precise PLAN 2.11 treatment planning system (TPS) was used for 3D-CRT planning. 50 Gy in
25 fractions were prescribed using tangential fields and 6-MV photons. Six different frequencies of bolus
applications (0, 5, 10, 15, 20, and 25) were administered. Cumulative dose-volume histograms were
generated for each bolus regimen. The minimum, maximum and mean skin doses associated with the bolus
regimens were compared. To test the accuracy of TPS dose calculations, experimental measurements
were performed using EBT gafchromic films.
Results: The mean, minimum and maximum skin doses were significantly increased with increasing days
of bolus applications (p < 0.001). The minimum skin doses for 0, 5, 10, 15, 20, and 25 days of bolus
applications were 73.0% ± 2.0%, 78.2% ± 2.0%, 83.3% ± 1.7%, 88.3% ± 1.6%, 92.2% ± 1.7%, and 93.8% ±
1.8%, respectively. The minimum skin dose increments between 20 and 25 (1.6% ± 1.0%), and 15 and 20
(4.0% ± 1.0%) days of bolus applications were significantly lower than the dose increments between 0 and
5 (5.2% ± 0.6%), 5 and 10 (5.1% ± 0.8%), and 10 and 15 (4.9% ± 0.8%) days of bolus applications (p < 0.001).
The maximum skin doses for 0, 5, 10, 15, 20, and 25 days of bolus applications were 110.1% ± 1.1%, 110.3%
± 1.1%, 110.5% ± 1.2%, 110.8% ± 1.3%, 111.2% ± 1.5%, and 112.2% ± 1.7%, respectively. The maximum
skin dose increments between 20 and 25 (1.0% ± 0.6%), and 15 and 20 (0.4% ± 0.3%) days of bolus
applications were significantly higher than the dose increments between 0 and 5 (0.2% ± 0.2%), 5 and 10
(0.2% ± 0.2%), and 10 and 15 (0.2% ± 0.2%) days of bolus applications (p ≤ 0.003). The TPS overestimated
the near-surface dose 10.8% at 2-mm below the skin surface.
Conclusion: In post-mastectomy 3D-CRT, using a 1-cm thick bolus in up to 15 of the total 25 fractions
increased minimum skin doses with a tolerable increase in maximum doses.
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Background
Post-mastectomy radiotherapy improves survival and
local control in patients with high risk breast cancer [1,2].
The chest wall is the most frequent site of recurrence and
delivering adequate radiation doses to the chest wall is
crucial to reducing the risk of treatment failure [3]. Keep-
ing radiation-induced side effects as low as possible, while
providing the intended dose to the chest wall remains a
challenge [4,5]. Definition of surface and superficial chest
wall doses provides valuable information for avoiding
near-surface recurrences and limiting severe early and late
skin reactions.
Tissue-equivalent material boluses, which are thick
enough to provide an adequate dose build-up in the skin
and superficial chest wall, are commonly used during
post-mastectomy radiotherapy. Skin dose contributions
of boluses and the dose delivered to skin and subcutane-
ous tissue are important, especially in locally advanced
breast cancer [6]. The American Society of Clinical Oncol-
ogy published treatment guidelines for post-mastectomy
radiotherapy in 2001. These guidelines stated that the
chest wall should be treated adequately but they did not
comment on the use of boluses [7].
To our knowledge, the mean, minimum, and maximum
skin doses associated with different durations of bolus
applications have not been reported. The purpose of this
prospective dosimetric study was to calculate the chest-
wall skin dose associated with various frequencies of
bolus applications in post-mastectomy three-dimensional
conformal radiotherapy (3D-CRT) and to provide
detailed information to aid in the selection of an appro-
priate bolus regimen in this clinical setting.
Methods
CT simulation
We performed CT-simulation of 22 patients immobilized
with a breast-board. Each patient was positioned supine
on the breast board with the ipsilateral arm abducted
above the head; board angles were tailored according to
the patient's anatomy. Patients were scanned with a 6
detector helical CT (CT Brilliance, Philips Medical Sys-
tems, Netherlands) with 5-mm slices from mid-neck to
mid-abdomen.
Volumes of interest
The external surface of the patient and lung contours were
defined by automated density gradient tracking then
edited and verified by physicians FA and RD. The chest
wall for the clinical target volume (CTV) was delineated
on corresponding transverse CT images (Figure 1) by FA
and RD using the external skin surface anteriorly, the rib-
soft tissue interface posteriorly, the inferior aspect of the
clavicular head superiorly and 1-cm below the contralat-
eral inframammary fold inferiorly. Medial and lateral bor-
ders of the CTV were delineated considering lateral border
of the sternum and the mid-axillary line, respectively.
To evaluate skin dose accurately, another volume includ-
ing 2-mm surface thickness of the CTV was contoured
(Figure 1) as skin structure.
The planning target volume (PTV) was defined by adding
5-mm to the CTV. However, the superficial contour of the
PTV was outlined 3-mm deep to the skin surface since the
build-up effect would cause apparent underdosage in the
dose-volume histograms (DVH) and difficulties in the
evaluation of the treatment plans.
3D-CRT planning
The Precise PLAN®2.11 (Elekta, Crawley, UK) treatment
planning system (TPS) was used for 3D-CRT planning.
The TPS calculates the dose distribution of the photon
beam using an irregular field algorithm based on data
measures in a phantom for different depths and field
sizes. The irregular field algorithm takes into account the
tissue inhomogeneity and uses an integration scheme to
evaluate the scatter component of the dose.
Two opposed tangential radiotherapy fields were created
(Figure 2). The beam centre was located in the chest wall.
To reduce the irradiated lung volume, incident beam
angles were used to match the fields at the dorsal field
edge non-divergently and lung tissue was shielded when
necessary. The nominal prescribed dose was 50 Gy in 25
fractions using 6-MV photons. The calculated dose was
normalized to a relevant point in the PTV to provide dose
homogeneity.
Skin structure (green line) and clinical target volume (dark- blue line) Figure 1
Skin structure (green line) and clinical target volume 
(dark-blue line).Journal of Experimental & Clinical Cancer Research 2009, 28:41 http://www.jeccr.com/content/28/1/41
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Although a uniform dose to the CTV within 95% to 107%
of the prescribed dose is recommended, a variation of plus
or minus 10% from the prescribed dose is widely used in
clinical practice [8]. In the present study, to accurately
evaluate the dose contribution of later bolus applications,
we planned that 90% to 110% of the prescribed dose to
the PTV would be delivered before the bolus applications.
Maximum doses higher than 110% of the prescribed
doses were ignored if they encompassed a point and not a
volume.
A 1-cm thick bolus with a 1 gr/cc density was placed over
the chest wall for 0, 5, 10, 15, 20, or 25 treatment days in
TPS calculations for all patients. Cumulative DVHs were
generated for each bolus regimen and for each patient.
The size of the dose bin used for the DVH calculation was
0.01 Gy. The DVHs of skin structures for 0, 5, 10, 15, 20
and 25 days of bolus applications in one case are shown
in Figure 3.
Dosimetric Analysis
To test the accuracy of TPS near-surface dose calculations,
solid plate phantom (Iba Dosimetry, Schwarzenbruck,
Germany) and EBT gafchromic (International Specialty
Products, Wayne, NJ, USA) films were used for both cali-
Tangential radiation field on digital reconstructed radiograph Figure 2
Tangential radiation field on digital reconstructed 
radiograph.
The dose-volume histograms of skin structures according to  days of bolus applications in one case Figure 3
The dose-volume histograms of skin structures 
according to days of bolus applications in one case. 
(White square) – 0 days; (upside down white triangle) – 5 
days; (white triangle) – 10 days; (White circle) – 15 days; 
(horizontal line) – 20 days; (small white square) – 25 days of 
bolus applications.Journal of Experimental & Clinical Cancer Research 2009, 28:41 http://www.jeccr.com/content/28/1/41
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bration and experimental measurements at a Synergy Plat-
form 6-MV linear accelerator (Elekta, Crawley, UK).
For calibration, 4 × 4 cm2 films were irradiated at 100-cm
fixed SSD (source-to-skin distance) and 5-cm depth with
different doses ranging from 4.128 cGy (5 MU) to 336.1
cGy (400 MU). After 24 hours later, irradiated films were
scanned using Epson, Expression 10000 XL (Seiko Epson
Corporation, Japan) scanner, read with Mephysto mc2
v1.3 (PTW, Freiburg, Germany) software and optic den-
sity-dose calibration curves were obtained.
For dose measurements, 4 × 4 cm2 films were placed at the
centre of the 10 × 10 cm2 field at specific depths (0, 1, 2,
3, 4, 5, 6, 8, 10, 12, 15, 20, 25 and 30-mm) and irradiated
at 100-cm fixed SSD with a dose of 83.25 cGy (100 MU).
Statistical analysis
We analyzed the dosimetric data of skin structure for all
treatment regimens. The mean, minimum and maximum
doses to skin in all bolus regimens were compared by the
Friedman test and Wilcoxon analysis using Statistical
Package for Social Sciences (SPSS), version 16.0. P-values
of 0.05 or less were considered statistically significant.
Values are expressed as mean (range) ± standard deviation
(SD) and percent of prescribed dose.
Results
The mean, minimum and maximum PTV doses before the
bolus applications were 101.8% (100.2–103.2%) ± 0.9%,
91.2% (90.0–94.5%) ± 1.2% and 109.4% (105.0–
110.6%) ± 1.3%, respectively.
Table 1 shows the mean, minimum, and maximum doses
to the skin according to days of bolus application. These
doses were significantly (p < 0.001) increased with
increased days of bolus application. The mean, minimum
and maximum doses to the skin structure with each bolus
regimen and in each plan are shown in Figures 4, 5 and 6.
Bolus use in all fractions provided a 20.8% ± 2.8% mini-
mum skin dose increment. The minimum skin dose incre-
ments between 20 and 25 (1.6% ± 1.0%), and 15 and 20
(4.0% ± 1.0%) days of bolus applications were signifi-
cantly lower than the dose increments between 0 and 5
(5.2% ± 0.6%), 5 and 10 (5.1% ± 0.8%), and 10 and 15
(4.9% ± 0.8%) days of bolus applications (p < 0.001).
Furthermore, the minimum skin dose increment between
20 and 25 (1.6% ± 1.0%) days of bolus application was
lower than the dose increment between 15 and 20 (4.0%
± 1.0%) days of bolus application (p < 0.001).
Bolus use in all fractions resulted in a 2.0% ± 1.2% maxi-
mum skin dose increment. The maximum skin dose incre-
ments between 20 and 25 (1.0% ± 0.6%), and 15 and 20
(0.4% ± 0.3%) days of bolus applications were signifi-
cantly higher than the dose increments between 0 and 5
(0.2% ± 0.2%), 5 and 10 (0.2% ± 0.2%), and 10 and 15
(0.2% ± 0.2%) days of bolus applications (p ≤ 0.003).
Furthermore, the maximum skin dose increment between
20 and 25 (1.0% ± 0.6%) days of bolus application was
higher than the dose increment between 15 and 20 (0.4%
± 0.3%) days of bolus application (p < 0.001).
The dose increase of the mean values between all bolus
frequencies was similar (p= 0.965).
Measurements using EBT gafchromic film revealed that
Precise PLAN®2.11 TPS overestimated near-surface dose
10.8% at 2-mm below the skin surface.
Discussion
Bolus thickness required to enhance surface dose is opti-
mized according to surface and build-up region dosime-
try. In the present study, a 1-cm bolus was used to increase
Mean values of skin structure doses according to bolus fre- quencies for all plans Figure 4
Mean values of skin structure doses according to 
bolus frequencies for all plans.
Minimum values of skin structure doses according to bolus  frequencies for all plans Figure 5
Minimum values of skin structure doses according to 
bolus frequencies for all plans.Journal of Experimental & Clinical Cancer Research 2009, 28:41 http://www.jeccr.com/content/28/1/41
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skin doses. This thickness was chosen because 6-MV pho-
ton energy with a 1.5-cm maximal depth was used for tan-
gential fields.
The skin dose contributions of 1-cm bolus material during
whole or a part of treatment duration were calculated in
this study. The results showed a trend of increasing mini-
mum skin dose when the days of bolus application were
increased. The minimum skin dose increments were
expected to be linear among the bolus durations. How-
ever, the minimum skin dose increments between 20 and
25 (1.6% ± 1.0%), and 15 and 20 (4.0% ± 1.0%) days of
bolus applications were significantly lower than the dose
increments between 0 and 5 (5.2% ± 0.6%), 5 and 10
(5.1% ± 0.8%), and 10 and 15 (4.9% ± 0.8%) days of
bolus applications while the maximum skin dose incre-
ments were significantly higher. TPS dose calculation
algorithm and treatment related factors such as delivery
technique, field size and angle of beam incidence are sup-
posed to be associated with these non-linear dose incre-
ments. Therefore, our results need to be clarified in further
dosimetric studies using different TPS, techniques, beam
energies, and bolus thicknesses.
Determining the necessary frequency of bolus treatments
is critically important in post-mastectomy radiotherapy,
since it influences the irradiated volume as well as the skin
doses. Although the literature contains several recommen-
dations for radiotherapy planning techniques, there are
few recommendations regarding bolus use [4,5,9-11]. The
optimal duration and the optimal thickness of the bolus
material still remain uncertain and change centre to centre
[7,12]. Wide regional variations in the use of boluses were
reported by Vu et al. in an international survey of radia-
tion oncologists and their opinions on the indications for
boluses in post-mastectomy radiotherapy [12].
Determining the difference between the calculated and
measured surface dose is useful when evaluating and com-
paring patient plans and also when optimizing the use of
boluses. Many factors affect the magnitude of the surface
dose, such as the delivery technique, field size, angle of
beam incidence, air gap and the use of bolus material and
beam modifiers [13-15]. Calculation of skin doses is diffi-
cult in most TPSs due to their inability to account for all
the factors that contribute to the surface dose. However,
the Monte Carlo TPSs and, to a lesser extent, the modern
true 3D algorithms are able to calculate skin doses [16-
18]. Doses calculated with different TPSs have been
reported to underestimate and overestimate measured
skin doses [15,19-23]. Measured skin doses also may dif-
fer according to the dosimetry used [13]. In the present
study, EBT gafchromic films were used to test the accuracy
of TPS and experimental measurements were performed
at 10 × 10 cm2 field at 100-cm fixed SSD since same tissue
equivalent field as in a post-mastectomy patient could not
be created to measure depth doses. The measurements
revealed that Precise PLAN®2.11 TPS overestimated the
near surface dose comparable to the literature [15,19-22].
However, the goal of the present study was to reveal the
trend in proportional skin doses with various frequencies
of bolus applications, using the same TPS to calculate
doses to the same skin structures.
The thickness of the epidermis varies between 0.05–1.5
mm, depending on the anatomic location. The Interna-
tional Commission on Radiological Protection and the
International Commission on Radiation Units and Meas-
urements recommends a depth of 0.07-mm, correspond-
ing to the epidermal and dermal layers, for practical skin
dose assessments [24,25]. Measuring the dose at that
depth is very difficult. Therefore, in the present study, skin
structure was defined as 2-mm surface thickness of the
CTV. Court et al. also used a 2-mm thick skin structure in
their investigation of the accuracy of skin dose calcula-
tions on a semi-cylindrical model of a neck or breast [15].
The superficial PTV contour is usually outlined 5-mm
deep to the skin surface to avoid apparent under-dosage in
the DVH due to build-up effects [4,26]. Although this is
reasonable in breast conserving surgery, it may result in
Maximum values of skin structure doses according to bolus  frequencies for all plans Figure 6
Maximum values of skin structure doses according to 
bolus frequencies for all plans.
Table 1: Mean values of mean, minimum, and maximum skin 
structure doses according to bolus frequencies
Bolus Regimen Mean ± SD* Minimum ± SD* Maximum ± SD*
0 100.0 ± 1.1 73.0 ± 2.0 110.1 ± 1.1
5 100.6 ± 1.1 78.2 ± 2.0 110.3 ± 1.1
10 101.3 ± 1.1 83.3 ± 1.7 110.5 ± 1.2
15 101.9 ± 1.1 88.3 ± 1.6 110.8 ± 1.3
20 102.6 ± 1.1 92.2 ± 1.7 111.2 ± 1.5
25 103.2 ± 1.1 93.8 ± 1.8 112.2 ± 1.7
* as percent of prescribed dose; SD, standard deviationJournal of Experimental & Clinical Cancer Research 2009, 28:41 http://www.jeccr.com/content/28/1/41
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wrong dose-volume information in post-mastectomy
radiotherapy, particularly in locally advanced breast can-
cer when the skin is close to or included in the target vol-
ume. Therefore, we believe that delineating a skin
structure in addition to the CTV and PTV would provide
important information in post-mastectomy treatment
planning. Furthermore, surface dose measurements for
the comparison of calculated and measured skin doses
would also help to define accurate skin dose deficit.
Conclusion
In post-mastectomy 3D-CRT, using a 1-cm thick bolus in
5, 10, and 15 of the total 25 fractions increased minimum
skin doses with a tolerable increase in maximum doses.
Hence, up to 15 days of bolus applications appear to be
the optimal bolus regimens. However, while deciding
duration of bolus application, the difference between cal-
culated and measured skin doses should also be consid-
ered, besides the calculated skin dose deficit in the TPS.
Abbreviations
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